| Market Capitalization (Millions $) |
10,423 |
| Shares
Outstanding (Millions) |
71 |
| Employees |
132 |
| Revenues (TTM) (Millions $) |
282 |
| Net Income (TTM) (Millions $) |
81 |
| Cash Flow (TTM) (Millions $) |
54 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development of peptide-based drugs. The company's primary goal is to discover and develop innovative treatments for gastrointestinal diseases and disorders.
Protagonist Therapeutics utilizes its proprietary technology platform called Protagonist Integrative Peptide Therapeutics (IPT) to identify and optimize peptides that can target specific disease pathways. The IPT platform combines computational modeling, synthetic chemistry, and biology to design and develop these peptide-based drugs.
The company's pipeline includes various drug candidates at different stages of development, targeting different indications such as inflammatory bowel disease, gastrointestinal cancers, and polycystic kidney disease. Protagonist Therapeutics aims to address unmet medical needs and provide novel treatment options for patients in these therapeutic areas.
With a focus on advancing its drug candidates through clinical trials and securing regulatory approvals, Protagonist Therapeutics aims to become a leading company in the field of peptide-based therapeutics. The company collaborates with pharmaceutical companies and research institutions to accelerate the development of its drug candidates and expand its pipeline.
Company Address: 7707 Gateway Boulevard, Suite 140 Newark 94560 CA
Company Phone Number: 474-0170 Stock Exchange / Ticker: NASDAQ PTGX
|
5.15 %